Cimetinib

Cimetinib (SOMCL-15-290) is a novel, orally administered small molecule tyrosine kinase inhibitor developed as a Class 1 anti-tumor drug. It is designed to selectively and potently inhibit Fibroblast Growth Factor Receptor (FGFR), Colony Stimulating Factor 1 Receptor (CSF1R), and Kinase Insert Domain Receptor (KDR, also known as VEGFR2). This multi-targeted mechanism aims to synergistically suppress tumor cell proliferation, remodel the tumor microenvironment, and overcome drug resistance, particularly cross-resistance to FGFR/KDR inhibitors. The drug also seeks to mitigate the severe clinical toxicities often associated with traditional multi-target inhibitors that primarily target KDR. Cimetinib was developed by the Chinese Academy of Sciences Institute of Drug Innovation / Shanghai Institute of Materia Medica, with clinical trials approved in China and an IND application being prepared for the US.

Brand names

simmitinib

Other names

希美替尼盐酸希美替尼